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miRNA, piRNA and snoRNA. The involvement of miRNAs
in the regulation of mammary gland tumorigenesis has been
widely studied while the role for other small non-coding
RNAs remains unclear. Here we summarize the involvement
of miRNA in breast cancer onset and progression through
regulating the cell cycle and cellular proliferation. The reg-
ulation of breast cancer stem cells and tumor regeneration
by miRNA is reviewed. In addition, the emerging evidence
demonstrating the involvement of piRNA and snoRNA in
breast cancer is briefly described.
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Abbreviations
siRNA small interfering RNA
miRNA microRNA
piRNA piwi-interacting RNA
EMT epithelial-to-mesenchymal transition
T-IC tumor-initiating cells
CSC cancer stem cells
CDK cyclin-dependent kinase
CAF cancer associated fibroblast
Introduction
Small non-coding RNAs are transcribed into mRNA but
remain untranslated in eukaryotic cells. They include siRNA
(small interfering RNA), miRNA (microRNA), piRNA
(piwi-interacting RNA) and snoRNA (small nucleolar
RNA). miRNAs are a class of multifunctional singled-
stranded small RNAwhich are ~20 nt in length and regulate
the stability or translational efficiency of targeted messenger
RNA depending on the base-pairing complementarity be-
tween the miRNA and its target mRNA [1, 2]. Although
over 1,000 miRNA sequences have been identified from the
tissues or cells of human origin and other species, as many
as 1,000 to 10,000 miRNAs per genome have been pre-
dicted [3, 4]. miRNAs regulate a broad range of biological
processes including timing of development, cell cycle pro-
gression, stem cell self-renewal, differentiation, cancer ini-
tiation, cancer cell proliferation, metastasis and apoptosis
[5–11].
Cancer is caused by multiple processes including uncon-
trolled cellular proliferation and inappropriate survival of
apoptotic cells [12]. Many regulatory factors switch on or
off genes that govern cell division and direct cellular prolif-
eration. miRNAs regulate gene expression and play impor-
tant roles in the onset and progression of tumorigenesis.
Breast cancer is the most common cancer among women.
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Abstract Small non-coding RNAs include siRNA, snoRNA small nucleolar RNAEmerging evidence demonstrates the involvement of
miRNA in mammary gland tumorigenesis, functioning ei-
ther as tumor suppressors or oncogenes [9]. Although the
current treatment of radiation therapy, chemotherapy and
hormone therapy slow mammary gland tumor growth, pro-
long survival and improve the quality of patients’ life,
metastatic breast cancer still remains incurable due to our
limited understanding of the molecular mechanisms through
which tumorigenesis and metastasis occur. As small non-
coding RNAs regulate gene expression and tumorigenesis,
they may represent a novel cancer therapy.
Aberrant Expression of miRNA in Breast Cancer
Unlike mRNA, miRNAs are transcribed but never translat-
ed. Some miRNAs are transcribed from non-coding regions
between genes, deriving from independent transcription
unit. Other miRNAs are transcribed together with coding
mRNAs from the coding region of the genome, deriving
from the introns of gene transcripts [13, 14]. miRNA gene
copy number gain/loss and miRNA gene mutation have
been observed in breast cancer resulting in the aberrant
expression of miRNA. The first study about the altered
expression of miRNAs in human breast cancer patients
and human breast cancer cell lines was reported in 2005
by Lorio et al., in which 29 miRNAs were identified with
aberrant expression based on microarray and northern blot
analysis of 76 breast tumor samples and 14 human breast
cell lines [15]. Zhang and colleagues analyzed 283 human
miRNA genes on 55 human breast primary tumors and 18
human breast cancer cell lines using array-based compara-
tive genomic hybridization. The results demonstrated a high
frequency (~72.8%) of gene copy number abnormality in
miRNA-containing regions in human breast cancer [16].
Wang et al. collected 68 patients with newly diagnosed
breast cancer and examined the expression of selected miR-
NAs in tumor and adjacent non-tumor tissues. miR-21, miR-
106a and miR-155 were significantly over-expressed in the
tumor specimens compared with normal controls, whereas
miR-126, miR-199a and miR-335 were significantly de-
creased in expression in the tumor samples [17]. Our studies
of the miR-17-92 cluster demonstrated decreased expression
of miR-17/20 in human breast cancer specimens compared
with matching normal breast tissue from the same patient
[18]. Subsequent analysis identified reduced miR-17/20 ex-
pression in node-positive compared with node-negative
breast cancers and demonstrated that miR-17/20 inhibited
breast cancer cell migration and invasion via a heterotypic
signaling [19].
Although the tendency for a global decrease of miRNA
expression in human cancers originally suggested a general
tumor suppressor function of miRNAs [20], subsequent
studies showing the aberrant expression of specific miRNAs
in breast cancer suggest miRNA-specific roles in breast
cancer onset and progression.
miRNA Regulation of Cell Cycle and Mammary Gland
Tumorigenesis
Many distinct miRNAs have been shown to regulate breast
cancer cell proliferation, apoptosis, cancer stem cell expan-
sion,andtumorigenesis.miRNAmayfunctionaseithertumor
suppressors or oncogenes depending on the cell type, culture
conditions, target genes and pathway. The involvement of
miRNA in mammary gland tumorigenesis has been reviewed
recently [21, 22]. Le et al. described the expression pattern
and regulatory network of key miRNAs in breast cancer,
including let-7, miR-34, miR-125, miR-200 family, miR-
205, miR-21, miR-10 and the miR-17-92 cluster [22]. Adams
et al. reviewed the miRNA regulation of estrogen signaling
pathway and ErbB2/HER signaling pathway in breast cancer
[21]. The understanding of how miRNAs are involved in
breast cancer through regulating the cell cycle remains rudi-
mentary. Herein we summarize the recent literature and re-
searchprogressonthemechanismbywhichmiRNAsregulate
the breast cancer cell cycle and cellular proliferation (Fig. 1).
Cyclin D1 is either overexpressed or amplified in ~50%
of breast cancer. The abundance of cyclin D1 is rate-limiting
in breast cancer cellular proliferation and G1-S phase tran-
sition [23, 24]. In addition, cyclin D1 is a critical down-
stream target of ErbB2-, Ras- and β-catenin- induced breast
cancers, and is sufficient for the induction of mammary
tumors when targeted to the mammary gland of mice. An-
tisense inhibition of cyclin D1 expression in vivo suppressed
the growth of NeuT-transformed mammary adenocarcinoma
cells in nude mice [25]. Conserved sequences of the cyclin
D1 3′UTR contain potential binding sites for multiple miR-
NAs including miR-17/20/106, miR-15/16, miR-23 and let-
7. miR-17/20 binds the cyclin D1 3′UTR, inhibiting the
expression of cyclin D1, resulting in cell cycle arrest at the
G1 phase and suppression of MCF-7 cell proliferation [18,
26]. The regulation of cyclin D1 expression by miR-17-92,
as well as miR-15/16, was confirmed by Deshpande et al.
[26]. The let-7 family functions as a tumor suppressor in a
variety of cancers including lung [27], colon [28], ovarian
[29] and breast cancer [30]. Schultz et al. demonstrated the
downregulation of cyclin D1 by miRNA let-7 in control of
cancer cell growth [31].
The regulation of cyclin D1 by miRNA is likely of broad
importance as cyclin D1 encodes the regulatory subunit of a
kinase that phosphorylates and inactivates the pRb family
proteins to inhibit DNA synthesis, and phosphorylates nu-
clear respiratory factor 1 (NRF-1) to inhibit mitochondria
biogenesis [32, 33]. Furthermore, cyclin D1 promotes breast
60 J Mammary Gland Biol Neoplasia (2012) 17:59–64epithelial cell angiogenesis and migration [34], and pro-
motes chromosomal instability which in turn contributes to
tumorigenesis [35].
The miR-221/222 cluster regulates the cell cycle, cell
growth and epithelial-to-mesenchymal transition (EMT) in
breast cancer. The expression of miR-221/222 is increased
in HER2/neu-positive primary human breast cancer [36].
The CDK inhibitors p27
KIP1 and p57
KIP2 are target genes
of miR-221/222. miR-221/222 inhibited p27
KIP1 and
p57
KIP2 abundance, facilitating G1-S phase transition, there-
by promoting cancer cell proliferation [36, 37]. Moreover,
miR-221/222 may contribute to the aggressive clinical be-
havior of basal-like breast cancers. The breast cancer basal-
like subtype-specific miRNAs, miR-221 and miR-222, pro-
mote EMT in breast cancer by targeting TRPS1 (trichorhino-
phalangeal syndrome type 1) which inhibits EMT by
repressing ZEB2 expression [38]. miR-221 and/or miR-222
expression in MCF-7 and T47D breast cancer cells decreased
ERα expression associated with tamoxifen resistance [39].
The onco-miRNA miR-21 is overexpressed in a wide
variety of cancers including breast cancer [40, 41]. miR-21
induced cellular proliferation, migration, invasion, EMT,
cancer stem cell characteristics and chemotherapy resistance
in human breast cancer [42, 43]. High miR-21 level is
associated with poor prognosis, advanced stage, positive
lymph node status and reduced survival time in breast
cancer. miR-21 promotes MCF-7 cellular proliferation in
part through inhibiting the expression of a tumor suppressor
gene programmed cell death 4 (PDCD4) [41]. In colon
cancer, miR-21 participates in a DNA damage-induced G2-
M checkpoint through suppressing the cell cycle regulator
Cdc25A [44]. A recent report demonstrated the miR-21
regulates the cell cycle through targeting Cdc25A in MCF-
7 breast cancer cells [45]. With a potential anti-cancer
chemical 3,3′-Diindolylmethane treatment, miR-21
expression increased, Cdc25A level decreased, and cellular
proliferation was inhibited [45].
miR-27a expression is upregulated in human breast can-
cer cell lines [46]. In MDA-MB-231 cells, miR-27a nega-
tively regulated the zinc finger ZBTB10 gene and Myt-1,
thereby promoting breast cancer cell proliferation [47]. Myt-1
phosphorylates and inactivates cdc2/cyclin B, inhibiting the
mitotic initiation of cell cycle [48]. miR-27a suppressed
Myt-1, increased cdc2/cyclin B activity and promoted the
G2-M checkpoint in MDA-MB-231 cells. Thus, distinct
miRNAs affect key genetic targets that govern distinct
cell-cycle checkpoints including cyclins, CDKs, CDK
inhibitors and the G2-M regulation apparatus. In addition
to cell-cycle control, breast tumor onset and progression
and breast tumor stem cells are also regulated by distinct
miRNAs.
miRNA Regulation of Breast Cancer Stem Cells
Cancer stem cells (CSCs) are characterized by their self-
renewal capacity, an ability to differentiate into non-
tumorigenic cell progeny, and their ability to seed tumors
when transplanted into animal hosts [49]. Cell surface
markers such as CD44, CD24, CD133, epithelial-specific
antigen and aldehyde dehydrogenase-1 are frequently used
to isolate and enrich CSCs. CD44
+CD24
-/lowLineage
- cells
were characterized as mammary gland tumorigenic CSCs
[50].
The involvement of miRNAs in regulating tumor forma-
tion by CSCs or tumor-initiating cells (T-IC) has been wide-
ly investigated. Let-7 expression is very low to undetectable
level in embryonic stem cells (ES cells) and increases with
differentiation. The same pattern of let-7 expression was
observed in breast cancer stem cells [30]. A comparison of
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Fig. 1 miRNA regulation of
mammary gland tumorigenesis
in control of the cell cycle.
Through targeting different
genes and different cyclin/CDK
complexes, miR-17/20 and let-7
regulate the G1-S transition;
miR-21 and miR-27a regulate
the G2-M checkpoint
J Mammary Gland Biol Neoplasia (2012) 17:59–64 61miRNA expression between breast T-IC and non-T-IC dem-
onstrated reduced let-7 expression in T-IC and increased
abundance with differentiation [30]. Transduction of breast
CSCs with let-7 reduced the proportion of undifferentiated
cells, inhibited cell proliferation, mammosphere formation,
and tumor formation in vivo [30].
Clarke and colleagues identified 37 miRNAs which were
differentially expressed between human breast CSCs
(CD44
+CD24
-/lowlineage
-)an dl in ea ge
- nontumorigenic breast
cancer cells [51]. miR-200 suppresses EMT in breast cancer
[52]. The miR-200 family members were downregulated in
human breast CSCs and normal mammary stem/progenitor
cells. Expression of miR-200 inhibited breast cancer stem cell
expansion in vitro, and suppressed the tumor formation ability
of human breast cancer stem cell in vivo [51].
Down-regulation of miR-34c was reported in human
breast T-IC [53]. Ectopic miR-34c expression reduced breast
T-ICs self-renewal, inhibited EMT and suppressed tumor
cell invasiveness via silencing Notch4 [53]. Zhu et al. found
the reduced miR-128 expression in human breast T-IC was
accompanied by Bmi-1 and ABCC5 overexpression, and
associated with chemotherapeutic resistance and poor sur-
vival [54]. Enforced miR-128 expression increased the sen-
sitivity of breast cancer cells to doxorubicin-induced
apoptosis and DNA damage [54].
Emerging evidence has demonstrated the importance of
CSCs in cancer initiation, cancer metastasis and drug resis-
tance. CSCs are believed to be one of the most promising
targets for cure of cancer. The discovery that non-coding RNAs
regulate CSCs widens our understanding of CSCs, and may
provide potential novel strategies for breast cancer therapy.
Other Non-coding Small RNAs in Breast Cancer
SnoRNAs primarily guide chemical modifications of other
RNAs. Deletion of chromosome 6q, including region 6q14-
q16, is frequently observed in breast cancer. The small non-
coding snoRNA U50 is a candidate tumor suppressor gene
in the 6q14-16 region, playing a role in the development
and/or progression of breast cancer [55]. Genomic deletion
and transcriptional downregulation of snoRNA U50 was
detected in breast cancer cell lines. Re-expression of
snoRNA U50 inhibited colony formation of the human
breast cancer cells Hs578t and MDA-MB-231.
piRNAs are small non-coding RNA that form RNA-
protein complexes through interactions with piwi proteins.
piRNA was initially discovered in germ line cells, and
considered as germ line-specific small RNAs [56]. Emerg-
ing evidence indicates that piRNA expression occurs in
somatic cells [57, 58] and piwil2 expression has been iden-
tified in human breast cancer cells [59]. High-throughput
deep sequencing identified a group of small RNAs matching
piRNA sequences in human breast cancer tissues and breast
cancer cell lines [60].
The study of these non-coding small RNAs in human
cancer is just starting. The mechanisms regulating snoRNAs
and piRNAs in human breast cancer remain unknown. The
identification of the expression signature of these non-
coding small RNAs in breast cancer subtypes, and an un-
derstanding of their functional significance to oncogene
expression, tumor initiation and tumor cell metastasis may
shed important new perspectives on the role of these non-
coding small RNAs in breast cancer.
Therapeutic Application of miRNA
Small non-coding RNA-based diagnostic and therapeutic
applications for human cancer are expected in the near
future. Although tumor-targeted delivery and local adminis-
tration are still major challenges to the practical application
of gene therapy for cancer, miRNA-based cancer therapeutic
approaches are being established and tested in animal mod-
els. Synthetic miRNA mimics or miRNA expression vectors
have been successfully applied to restore or overexpress
miRNA in vitro. Chemically modified LNA anti-sense
miRNA inhibitor and other approaches have been used to
block miRNA function in cells. Kim et al. recently reported
significant anti-tumor effect of virus-mediated delivery of
miR-145 combined with 5-FU to treat breast cancer [61].
Intranasal delivery of let-7 [62] and intravenous delivery of
miR-34a mimics [63] for non-small-cell lung cancer treat-
ment and a virus-mediated delivery of miR-26a for liver
cancer treatment in mouse model [64] demonstrate the
promise of miRNA for treatment of cancer.
Concluding Remarks
Dysregulated expression of miRNAs has implicated compo-
nents of the non-coding genome as either oncogenes or
tumor suppressors of breast cancer. Experimental evidence
has shown specific miRNAs regulating the initiation, pro-
gression, metastasis and drug resistance of breast cancer via
control of the cell cycle, altering cellular proliferation, alter-
ing cellular apoptosis and/or controlling the population of
tumor stem cells. Dysregulated miRNA expression has also
been observed in cancer associated fibroblasts (CAF) and in
the systemic circulation [65, 66]. The circulating miRNAs
have the potential to serve as novel diagnostic and prognos-
tic biomarkers for breast cancer. A specific subset of dysre-
gulated miRNAs in breast cancer cells may serve as targets
for gene therapy either alone or as an adjuvant treatment to
current clinical protocols for breast cancer patients.
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